AR113964A1 - Carbamoíl ciclohexil ácidos ligados a n de triazol como antagonistas de lpa - Google Patents
Carbamoíl ciclohexil ácidos ligados a n de triazol como antagonistas de lpaInfo
- Publication number
- AR113964A1 AR113964A1 ARP180103700A ARP180103700A AR113964A1 AR 113964 A1 AR113964 A1 AR 113964A1 AR P180103700 A ARP180103700 A AR P180103700A AR P180103700 A ARP180103700 A AR P180103700A AR 113964 A1 AR113964 A1 AR 113964A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- haloalkyl
- alkoxyalkyl
- aminoalkyl
- hydroxyalkyl
- Prior art date
Links
- -1 CYCLOHEXYL Chemical class 0.000 title abstract 7
- 239000002253 acid Substances 0.000 title 1
- 150000007513 acids Chemical class 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 150000003852 triazoles Chemical class 0.000 title 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 12
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 11
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 9
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 9
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 8
- 125000004994 halo alkoxy alkyl group Chemical group 0.000 abstract 8
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 8
- 125000003545 alkoxy group Chemical group 0.000 abstract 7
- 125000003282 alkyl amino group Chemical group 0.000 abstract 7
- 125000000623 heterocyclic group Chemical group 0.000 abstract 7
- 125000005843 halogen group Chemical group 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 5
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 150000002431 hydrogen Chemical class 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 1
- 125000004008 6 membered carbocyclic group Chemical group 0.000 abstract 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 abstract 1
- 102000004137 Lysophosphatidic Acid Receptors Human genes 0.000 abstract 1
- 108090000642 Lysophosphatidic Acid Receptors Proteins 0.000 abstract 1
- 229940124639 Selective inhibitor Drugs 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 229910052805 deuterium Inorganic materials 0.000 abstract 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C249/00—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C249/04—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of oximes
- C07C249/06—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of oximes by nitrosation of hydrocarbons or substituted hydrocarbons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
- C07C403/04—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Compuestos de la fórmula (1), o un estereoisómero, un tautómero, o una sal o un solvato de aquel aceptable desde el punto de vista farmacéutico, en donde todas las variables son como se definen en la presente. Estos compuestos son inhibidores selectivos del receptor de LPA. Reivindicación 1: Un compuesto caracterizado por la fórmula (1), o un estereoisómero, un tautómero, una sal o un solvato de aquellos aceptables desde el punto de vista farmacéutico, en donde: X¹, X², X³ y X⁴ son, cada uno independientemente, CR⁶ o N; siempre que no más de dos de X¹, X², X³ o X⁴ sean N; uno de Q¹, Q² y Q³ es NR⁵, y los otros dos son N; y el circulo discontinuo indica enlaces opcionales que forman un anillo aromático; Y¹ es O ó NR³; Y² es un resto seleccionado del grupo de fórmulas (2); Y³ es O ó NR⁴ᵃ; siempre que (i) Y¹ e Y³ no sean ambos O, y (ii) cuando Y² es C(O), Y¹ no es O; L es un enlace covalente o C₁₋₄ alquileno sustituido con 0 a 4 R⁷; R¹ es (-CH₂)ₐR⁹; a es un entero de 0 ó 1; R² es, cada uno independientemente, halo, ciano, hidroxilo, amino, C₁₋₆ alquilo, C₃₋₆ cicloalquilo, C₄₋₆ heterociclilo, alquilamino, haloalquilo, hidroxialquilo, aminoalquilo, alcoxi, alcoxialquilo, haloalcoxialquilo o haloalcoxi; n es un entero de 0, 1 ó 2; R³ y R⁴ᵃ son, cada uno independientemente, hidrógeno, C₁₋₆ alquilo, haloalquilo, hidroxialquilo, aminoalquilo, alcoxialquilo, haloalcoxialquilo, alcoxi o haloalcoxi; R⁴ es C₁₋₁₀ alquilo, C₁₋₁₀ alquilo deuterado, C₁₋₁₀ haloalquilo, C₁₋₁₀ alquenilo, C₃₋₈ cicloalquilo, arilo de 6 a 10 miembros, heterociclilo de 3 a 8 miembros, -(C₁₋₆ alquilen)-(C₃₋₈ cicloalquilo), -(C₁₋₆ alquilen)-(arilo de 6 a 10 miembros), -(C₁₋₆ alquilen)-(heterociclilo de 3 a 8 miembros) o -(C₁₋₆ alquilen)-(heteroarilo de 5 a 6 miembros); en donde cada uno de alquilo, alquenilo, cicloalquilo, arilo, heterociclilo y heteroarilo, solo o como parte de otra porción, se sustituye independientemente con 0 a 3 R⁸; o de manera alternativa, R³ y R⁴, junto con los átomos a los que están unidos, forman una porción anillo heterocíclico de 4 a 9 miembros que se sustituye con 0 a 3 R⁸; R⁵ es hidrógeno, C₁₋₆ alquilo, alquilamino, haloalquilo, hidroxialquilo, aminoalquilo, alcoxialquilo, haloalcoxialquilo, alcoxi o haloalcoxi; R⁶ es hidrógeno, halo, ciano, hidroxilo, amino, C₁₋₆, alquilo, alquilamino, haloalquilo, hidroxialquilo, aminoalquilo, alcoxialquilo, haloalcoxialquilo, alcoxi o haloalcoxi; R⁷ es halo, oxo, ciano, hidroxilo, amino, C₁₋₆ alquilo, C₃₋₆ cicloalquilo, C₄₋₆ heterociclilo, alquilamino, haloalquilo, hidroxialquilo, aminoalquilo, alcoxialquilo, haloalcoxialquilo, alcoxi o haloalcoxi; R⁸ son, cada uno independientemente, deuterio, halo, hidroxilo, amino, ciano, C₁₋₆ alquilo, C₁₋₆ alquilo deuterado, C₂₋₆ alquenilo, C₂₋₆ alquinilo, alquilamino, haloalquilo, hidroxialquilo, aminoalquilo, alcoxialquilo, haloalcoxialquilo, alcoxi, haloalcoxi, -CHO, fenilo o heteroarilo de 5 a 6 miembros; o de manera alternativa, dos R⁸, junto con los átomos a los que están unidos, forman un anillo carbocíclico de 3 a 6 miembros o un anillo heterocíclico de 3 a 6 miembros, cada uno de los cuales se sustituye independientemente con 0 a 3 R¹²; R⁹ se selecciona de -CN, -C(O)OR¹⁰, -C(O)NR¹¹ᵃR¹¹ᵇ, o un resto seleccionado del grupo de fórmulas (3); Rᵉ es C₁₋₆ alquilo, C₃₋₆ cicloalquilo, haloalquilo, hidroxialquilo, aminoalquilo, alcoxialquilo o haloalcoxialquilo; R¹⁰ es hidrógeno o C₁₋₁₀ alquilo; R¹¹ᵃ y R¹¹ᵇ son cada uno independientemente hidrógeno, C₁₋₆ alquilo, C₃₋₆ cicloalquilo, C₄₋₆; heterociclilo, alquilamino, haloalquilo, hidroxialquilo, aminoalquilo, alcoxialquilo, haloalcoxialquilo, alcoxi o haloalcoxi, y R¹² es halo, ciano, hidroxilo, amino, C₁₋₆ alquilo, alquilamino, haloalquilo, hidroxialquilo, aminoalquilo, alcoxialquilo, haloalcoxialquilo, alcoxi, haloalcoxi, fenilo o heteroarilo de 5 a 6 miembros.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762607399P | 2017-12-19 | 2017-12-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR113964A1 true AR113964A1 (es) | 2020-07-01 |
Family
ID=65003579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180103700A AR113964A1 (es) | 2017-12-19 | 2018-12-18 | Carbamoíl ciclohexil ácidos ligados a n de triazol como antagonistas de lpa |
Country Status (29)
| Country | Link |
|---|---|
| US (4) | US10662172B2 (es) |
| EP (2) | EP4011875A1 (es) |
| JP (1) | JP7274486B6 (es) |
| KR (1) | KR102702229B1 (es) |
| CN (2) | CN112189010A (es) |
| AR (1) | AR113964A1 (es) |
| AU (1) | AU2018392321B2 (es) |
| CA (1) | CA3085586C (es) |
| CL (1) | CL2020001547A1 (es) |
| CY (1) | CY1124863T1 (es) |
| DK (1) | DK3710438T3 (es) |
| EA (1) | EA202091506A1 (es) |
| ES (1) | ES2898364T3 (es) |
| HR (1) | HRP20211918T8 (es) |
| HU (1) | HUE057366T2 (es) |
| IL (1) | IL275348B2 (es) |
| LT (1) | LT3710438T (es) |
| MX (1) | MX394467B (es) |
| MY (1) | MY199103A (es) |
| NZ (1) | NZ766284A (es) |
| PE (1) | PE20210655A1 (es) |
| PL (1) | PL3710438T3 (es) |
| PT (1) | PT3710438T (es) |
| RS (1) | RS62710B1 (es) |
| SG (1) | SG11202005699QA (es) |
| SI (1) | SI3710438T1 (es) |
| SM (1) | SMT202100716T1 (es) |
| TW (1) | TWI830713B (es) |
| WO (1) | WO2019126090A1 (es) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR108838A1 (es) | 2016-06-21 | 2018-10-03 | Bristol Myers Squibb Co | Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa |
| CN112041302B (zh) | 2017-12-19 | 2024-11-19 | 百时美施贵宝公司 | 作为lpa拮抗剂的吡唑o-连接的氨基甲酰基环己基酸 |
| EP3728240B1 (en) | 2017-12-19 | 2022-06-29 | Bristol-Myers Squibb Company | Isoxazole o-linked carbamoyl cyclohexyl acids as lpa antagonists |
| TWI830713B (zh) | 2017-12-19 | 2024-02-01 | 美商必治妥美雅史谷比公司 | 作為lpa拮抗劑之三唑n-連接之胺甲醯基環己基酸 |
| CN112041304B (zh) * | 2017-12-19 | 2025-03-07 | 百时美施贵宝公司 | 作为lpa拮抗剂的异噁唑n-连接的氨基甲酰基环己基酸 |
| AU2018392332B2 (en) | 2017-12-19 | 2023-08-03 | Turning Point Therapeutics, Inc. | Macrocyclic compounds for treating disease |
| ES2924704T3 (es) | 2017-12-19 | 2022-10-10 | Bristol Myers Squibb Co | Pirazol azoles del ácido ciclohexílico como antagonistas de LPA |
| WO2019126086A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Cyclohexyl acid isoxazole azines as lpa antagonists |
| ES2936517T3 (es) | 2017-12-19 | 2023-03-17 | Bristol Myers Squibb Co | Triazol azinas de ácido ciclohexílico como antagonistas de LPA |
| ES2962367T3 (es) | 2017-12-19 | 2024-03-18 | Bristol Myers Squibb Co | Acidos carbamoil ciclohexílicos N-enlazados a pirazol como antagonistas de receptores del ácido lisofosfatídico (LPA) |
| CA3085938A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Cyclohexyl acid triazole azoles as lpa antagonists |
| CN112074515B (zh) | 2017-12-19 | 2025-01-10 | 百时美施贵宝公司 | 作为lpa拮抗剂的环己基酸异噁唑唑类 |
| ES2944304T3 (es) | 2017-12-19 | 2023-06-20 | Bristol Myers Squibb Co | Pirazol azinas de ácido ciclohexílico como antagonistas de LPA |
| JP7412424B2 (ja) | 2018-09-18 | 2024-01-12 | ブリストル－マイヤーズ スクイブ カンパニー | Ｌｐａアンタゴニストとしてのオキサビシクロ酸 |
| JP7427658B2 (ja) | 2018-09-18 | 2024-02-05 | ブリストル－マイヤーズ スクイブ カンパニー | Ｌｐａアンタゴニストとしてのシクロペンチル酸 |
| CN113260310A (zh) * | 2018-10-15 | 2021-08-13 | 百时美施贵宝公司 | 用于成像lpa1受体的放射性配体 |
| CN111434653A (zh) * | 2019-01-15 | 2020-07-21 | 武汉朗来科技发展有限公司 | 三氮唑类化合物及其制备方法与用途 |
| IL289951B2 (en) * | 2019-07-30 | 2025-10-01 | Taisho Pharmaceutical Co Ltd | Urea compound as an LPA1 receptor antagonist |
| CN110590599B (zh) * | 2019-09-30 | 2022-07-26 | 大连民族大学 | 一种群体感应信号分子结构类似物及其制备方法 |
| KR102775995B1 (ko) | 2019-11-15 | 2025-03-11 | 길리애드 사이언시즈, 인코포레이티드 | Lpa 수용체 길항제로서의 트라이아졸 카르바메이트 피리딜 설폰아미드 및 이의 용도 |
| JP2023505704A (ja) | 2019-12-12 | 2023-02-10 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | Ｌｐａ受容体２阻害剤としてのキナゾリン誘導体 |
| US20230043672A1 (en) | 2019-12-12 | 2023-02-09 | Chiesi Farmaceutici S.P.A. | Aromatic amido derivatives as lpa receptor 2 inhibitors |
| CN114746425A (zh) | 2019-12-12 | 2022-07-12 | 奇斯药制品公司 | 作为lpa受体2抑制剂的噻吩并嘧啶衍生物 |
| TWI843503B (zh) | 2020-06-03 | 2024-05-21 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| CA3185689A1 (en) | 2020-06-03 | 2021-12-09 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| WO2022013378A1 (en) | 2020-07-16 | 2022-01-20 | Chiesi Farmaceutici S.P.A. | Amido cyclohexane acid derivatives as lpa receptor inhibitors |
| WO2022100623A1 (zh) * | 2020-11-10 | 2022-05-19 | 武汉人福创新药物研发中心有限公司 | 氮取代杂环噻吩类化合物及其用途 |
| US12521413B2 (en) | 2020-11-25 | 2026-01-13 | Yeditepe Universitesi | Molecular basis of fatty liver inhibition by sodium borates |
| WO2022174882A1 (en) | 2021-02-16 | 2022-08-25 | Chiesi Farmaceutici S.P.A. | 5-membered heterocyclyl carbamate derivatives as dual lpa receptor 1 and lpa receptor 2 inhibitors |
| WO2022174883A1 (en) | 2021-02-16 | 2022-08-25 | Chiesi Farmaceutici S.P.A. | 5-membered heterocyclyl derivatives as dual lpa receptor 1 and lpa receptor 2 inhibitors |
| US20240190860A1 (en) | 2021-03-24 | 2024-06-13 | Chiesi Farmaceutici S.P.A. | 8-cyclo-substituted quinazoline derivatives as lpa receptor 2 inhibitors |
| AU2022273631B2 (en) | 2021-05-11 | 2025-04-17 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| WO2022241023A1 (en) * | 2021-05-13 | 2022-11-17 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| CN118541360A (zh) | 2021-12-08 | 2024-08-23 | 吉利德科学公司 | Lpa受体拮抗剂及其用途 |
| EP4452965A1 (en) | 2021-12-23 | 2024-10-30 | Chiesi Farmaceutici S.p.A. | Cyclohexane acid derivatives as lpa receptor inhibitors |
| WO2023170025A1 (en) | 2022-03-08 | 2023-09-14 | Chiesi Farmaceutici S.P.A. | Amido cyclopropyl derivatives as lpa receptor inhibitors |
| WO2025051267A1 (zh) * | 2023-09-08 | 2025-03-13 | 西藏海思科制药有限公司 | 一种lpar1拮抗剂及其用途 |
| WO2025051266A1 (zh) * | 2023-09-08 | 2025-03-13 | 西藏海思科制药有限公司 | 杂芳环衍生物的lpar1拮抗剂及其用途 |
| WO2025162421A1 (zh) * | 2024-02-04 | 2025-08-07 | 西藏海思科制药有限公司 | Lpar1拮抗剂及其用途 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2320320T3 (es) | 2000-02-18 | 2009-05-21 | Kyowa Hakko Kirin Co., Ltd. | Nuevos compuestos de isoxazol y tiazol y uso de los mismos como farmacos. |
| ATE447970T1 (de) | 2001-02-08 | 2009-11-15 | Ono Pharmaceutical Co | Mittel zur behandlung von harnwegserkrankungen, umfassend mittel zur kontrolle des lpa-rezeptors |
| WO2005012269A1 (ja) | 2003-08-05 | 2005-02-10 | Ajinomoto Co., Inc. | 新規アゾール化合物 |
| US7432271B2 (en) | 2003-09-02 | 2008-10-07 | Bristol-Myers Squibb Company | Pyrazolyl inhibitors of 15-lipoxygenase |
| DE102004038403B4 (de) | 2004-08-07 | 2006-08-31 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur Herstellung der enantiomeren Formen von cis-konfigurierten 3-Hydroxycyclohexancarbonsäure-Derivaten |
| US20080186971A1 (en) | 2007-02-02 | 2008-08-07 | Tarari, Inc. | Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic |
| GB0806794D0 (en) | 2008-04-15 | 2008-05-14 | Ludwig Inst Cancer Res | Therapeutic compounds |
| JP2013501064A (ja) | 2009-08-04 | 2013-01-10 | アミラ ファーマシューティカルス，インコーポレーテッド | リゾホスファチジン酸受容体アンタゴニストとしての化合物 |
| GB2474120B (en) | 2009-10-01 | 2011-12-21 | Amira Pharmaceuticals Inc | Compounds as Lysophosphatidic acid receptor antagonists |
| GB2474748B (en) | 2009-10-01 | 2011-10-12 | Amira Pharmaceuticals Inc | Polycyclic compounds as lysophosphatidic acid receptor antagonists |
| US8742097B2 (en) | 2010-11-09 | 2014-06-03 | Hoffmann-La Roche Inc. | Triazole compounds I |
| US8785442B2 (en) | 2011-01-30 | 2014-07-22 | Curegenix, Inc. | Compound as antagonist of lysophosphatidic acid receptor, composition, and use thereof |
| WO2012137982A2 (en) | 2011-04-05 | 2012-10-11 | Takeda Pharmaceutical Company Limited | Sulfonamide derivative and use thereof |
| WO2012138648A1 (en) | 2011-04-06 | 2012-10-11 | Irm Llc | Compositions and methods for modulating lpa receptors |
| WO2013070879A1 (en) | 2011-11-10 | 2013-05-16 | Bristol-Myers Squibb Company | Methods for treating spinal cord injury with lpa receptor antagonists |
| WO2013085824A1 (en) | 2011-12-04 | 2013-06-13 | Angion Biomedica Corp. | Small molecule anti-fibrotic compounds and uses thereof |
| KR20150021057A (ko) * | 2012-06-20 | 2015-02-27 | 에프. 호프만-라 로슈 아게 | Lpar 길항제로서의 n-알킬트라이아졸 화합물 |
| TW201437200A (zh) * | 2013-01-15 | 2014-10-01 | Intermune Inc | 溶血磷脂酸受體拮抗劑 |
| AU2014232383B2 (en) | 2013-03-15 | 2019-01-17 | Epigen Biosciences, Inc. | Heterocyclic compounds useful in the treatment of disease |
| WO2016044556A2 (en) | 2014-09-17 | 2016-03-24 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| JP6853619B2 (ja) | 2015-01-16 | 2021-03-31 | 大塚製薬株式会社 | シアノトリアゾール化合物の医薬用途 |
| AR108838A1 (es) | 2016-06-21 | 2018-10-03 | Bristol Myers Squibb Co | Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa |
| ES2924704T3 (es) | 2017-12-19 | 2022-10-10 | Bristol Myers Squibb Co | Pirazol azoles del ácido ciclohexílico como antagonistas de LPA |
| CA3085938A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Cyclohexyl acid triazole azoles as lpa antagonists |
| ES2944304T3 (es) | 2017-12-19 | 2023-06-20 | Bristol Myers Squibb Co | Pirazol azinas de ácido ciclohexílico como antagonistas de LPA |
| CN112041302B (zh) | 2017-12-19 | 2024-11-19 | 百时美施贵宝公司 | 作为lpa拮抗剂的吡唑o-连接的氨基甲酰基环己基酸 |
| WO2019126086A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Cyclohexyl acid isoxazole azines as lpa antagonists |
| TWI830713B (zh) | 2017-12-19 | 2024-02-01 | 美商必治妥美雅史谷比公司 | 作為lpa拮抗劑之三唑n-連接之胺甲醯基環己基酸 |
| ES2962367T3 (es) | 2017-12-19 | 2024-03-18 | Bristol Myers Squibb Co | Acidos carbamoil ciclohexílicos N-enlazados a pirazol como antagonistas de receptores del ácido lisofosfatídico (LPA) |
| CN112074515B (zh) | 2017-12-19 | 2025-01-10 | 百时美施贵宝公司 | 作为lpa拮抗剂的环己基酸异噁唑唑类 |
| EP3728240B1 (en) | 2017-12-19 | 2022-06-29 | Bristol-Myers Squibb Company | Isoxazole o-linked carbamoyl cyclohexyl acids as lpa antagonists |
| CN112041304B (zh) | 2017-12-19 | 2025-03-07 | 百时美施贵宝公司 | 作为lpa拮抗剂的异噁唑n-连接的氨基甲酰基环己基酸 |
| ES2936517T3 (es) | 2017-12-19 | 2023-03-17 | Bristol Myers Squibb Co | Triazol azinas de ácido ciclohexílico como antagonistas de LPA |
| AU2018392332B2 (en) | 2017-12-19 | 2023-08-03 | Turning Point Therapeutics, Inc. | Macrocyclic compounds for treating disease |
-
2018
- 2018-12-18 TW TW107145551A patent/TWI830713B/zh not_active IP Right Cessation
- 2018-12-18 SG SG11202005699QA patent/SG11202005699QA/en unknown
- 2018-12-18 DK DK18830680.7T patent/DK3710438T3/da active
- 2018-12-18 MY MYPI2020003100A patent/MY199103A/en unknown
- 2018-12-18 HR HRP20211918TT patent/HRP20211918T8/hr unknown
- 2018-12-18 WO PCT/US2018/066117 patent/WO2019126090A1/en not_active Ceased
- 2018-12-18 EP EP21203235.3A patent/EP4011875A1/en not_active Withdrawn
- 2018-12-18 CA CA3085586A patent/CA3085586C/en active Active
- 2018-12-18 EA EA202091506A patent/EA202091506A1/ru unknown
- 2018-12-18 PL PL18830680T patent/PL3710438T3/pl unknown
- 2018-12-18 US US16/223,169 patent/US10662172B2/en active Active
- 2018-12-18 PT PT188306807T patent/PT3710438T/pt unknown
- 2018-12-18 KR KR1020207020553A patent/KR102702229B1/ko active Active
- 2018-12-18 JP JP2020533840A patent/JP7274486B6/ja active Active
- 2018-12-18 RS RS20211542A patent/RS62710B1/sr unknown
- 2018-12-18 CN CN201880080910.1A patent/CN112189010A/zh active Pending
- 2018-12-18 NZ NZ766284A patent/NZ766284A/en not_active IP Right Cessation
- 2018-12-18 SM SM20210716T patent/SMT202100716T1/it unknown
- 2018-12-18 CN CN202011353094.2A patent/CN112521368B/zh active Active
- 2018-12-18 ES ES18830680T patent/ES2898364T3/es active Active
- 2018-12-18 EP EP18830680.7A patent/EP3710438B1/en active Active
- 2018-12-18 PE PE2020000746A patent/PE20210655A1/es unknown
- 2018-12-18 SI SI201830475T patent/SI3710438T1/sl unknown
- 2018-12-18 AU AU2018392321A patent/AU2018392321B2/en active Active
- 2018-12-18 MX MX2020006315A patent/MX394467B/es unknown
- 2018-12-18 LT LTEPPCT/US2018/066117T patent/LT3710438T/lt unknown
- 2018-12-18 HU HUE18830680A patent/HUE057366T2/hu unknown
- 2018-12-18 AR ARP180103700A patent/AR113964A1/es unknown
-
2020
- 2020-01-16 US US16/744,303 patent/US11008300B2/en active Active
- 2020-06-10 CL CL2020001547A patent/CL2020001547A1/es unknown
- 2020-06-14 IL IL275348A patent/IL275348B2/en unknown
-
2021
- 2021-04-07 US US17/224,161 patent/US11697646B2/en active Active
- 2021-12-14 CY CY20211101119T patent/CY1124863T1/el unknown
-
2023
- 2023-05-22 US US18/321,092 patent/US12195444B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR113964A1 (es) | Carbamoíl ciclohexil ácidos ligados a n de triazol como antagonistas de lpa | |
| AR113965A1 (es) | Triazol azoles ciclohexil ácidos como antagonistas de lpa | |
| AR120338A1 (es) | Piridazinonas como inhibidores de parp7 | |
| AR127309A2 (es) | Derivados de piridazinona | |
| AR110139A1 (es) | COMPUESTOS MONO Y ESPIROCÍCLICOS QUE CONTIENEN CICLOBUTANO Y AZETIDINA COMO INHIBIDORES DE LA INTEGRINA aV | |
| AR101189A1 (es) | Heterociclos nitrogenados antiproliferativos y sus métodos de uso | |
| AR114793A1 (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de los mismos | |
| AR110153A1 (es) | ÁCIDOS PROPIÓNICOS 3-SUSTITUIDOS COMO INHIBIDORES DE LA INTEGRINA aV | |
| AR117424A1 (es) | Inhibidores de los receptores erbb | |
| AR090945A1 (es) | Moduladores de la via del complemento y usos de los mismos | |
| AR100033A1 (es) | Compuestos y composiciones para inhibir la actividad de shp2 | |
| AR089568A1 (es) | Compuestos heterociclicos y sus metodos de usos | |
| AR098666A1 (es) | Compuestos de biarilacetamida y sus métodos de uso | |
| AR091279A1 (es) | Inhibidores macrociclicos de virus flaviviridae | |
| AR089143A1 (es) | Triazolopiridinas sustituidas con actividad inhibidora de ttk | |
| AR109709A1 (es) | Inhibidores de la fosfatidilinositol 3-quinasa | |
| AR107321A1 (es) | Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos | |
| AR106301A1 (es) | Composiciones de pirrolpirimidina como inhibidores de quinasas | |
| AR100808A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR099495A1 (es) | Derivados de amida, antagonistas de orexina | |
| AR112907A1 (es) | Pirazoles inhibidores de monoacilglicerol lipasa (magl) | |
| AR108864A1 (es) | Agentes antibacterianos | |
| AR091534A1 (es) | Derivados de sulfonamida y metodos de uso de los mismos para mejorar la farmacocinetica de un farmaco | |
| AR112794A1 (es) | Compuestos heteroaromáticos sustituidos con cicloolefinas y su uso en el tratamiento de enfermedades inducidas por mutaciones idh | |
| AR117989A1 (es) | Inhibidores de o-glucoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa de éter bicíclico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |